BiotechTube

Ad26.ZEBOV + MVA-BN-Filo

Phase 3Terminated
0 watching 0 views this week📈 Rising
74
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Hemorrhagic Fever, Ebola

Conditions

Hemorrhagic Fever, Ebola

Trial Timeline

May 31, 2016 → Dec 13, 2021

NCT ID
NCT02661464

About Ad26.ZEBOV + MVA-BN-Filo

Ad26.ZEBOV + MVA-BN-Filo is a phase 3 stage product being developed by Bavarian Nordic for Hemorrhagic Fever, Ebola. The current trial status is terminated. This product is registered under clinical trial identifier NCT02661464. Target conditions include Hemorrhagic Fever, Ebola.

Hype Score Breakdown

Clinical
27
Activity
18
Company
7
Novelty
9
Community
10

Clinical Trials (1)

NCT IDPhaseStatus
NCT02661464Phase 3Terminated

Competing Products

10 competing products in Hemorrhagic Fever, Ebola

See all competitors
ProductCompanyStageHype Score
LP-10Lipella PharmaceuticalsPhase 2
44
BAF312 solution + Matching Placebo for BAF312 solution + BAF312 tablet + Matching Placebo for BAF312 tabletNovartisPhase 2
52
ALN-6400 + PlaceboAlnylam PharmaceuticalsPhase 1/2
38
AVI-7537United TherapeuticsPhase 1
30
AVI-7288United TherapeuticsPhase 1
30
Placebo + AVI-6002United TherapeuticsPhase 1
30
AVI-6003 + PlaceboUnited TherapeuticsPhase 1
30
Tranexamic acid first, than placebo + First placebo, than Tranexamic acid.BaxterPhase 3
74
Ribavirin (Virazole) InjectionBausch HealthPhase 2
47
BGE-117, 4mg + BGE-117, 12mgBioAge LabsPhase 2
47

Other Products from Bavarian Nordic

IMVAMUNE®Approved
82
VAXCHORA (Cholera Vaccine, Live, Oral)Approved
82
PROSTVAC-V + PROSTVAC-F + GM-CSF + PlaceboPhase 3
74
PXVX0200 + placeboPhase 3
74
MVA-BN standard regimen + MVA-BN standard regimen (Administered as PEP)Phase 3
74